Variable | All patients (n = 524) % | POD24 group (n = 143) % | Non-POD24 group (n = 381) % | p-value |
---|---|---|---|---|
Median age, range (yrs) | 63 (18–98) | 66 (19–98) | 62 (18–93) | 0.003 |
Sex, n (%) | 0.57 | |||
Males | 268 (51) | 76 (53) | 192 (50) | |
Females | 256 (49) | 67 (47) | 189 (50) | |
BMI ≤ 30 kg/m2, n (%) | 340 (69) | 94 (72) | 246 (68) | 0.34 |
MZL subtype, n (%) | 0.04 | |||
NMZL | 124 (24) | 45 (32) | 79 (21) | |
SMZL | 135 (26) | 33 (23) | 102 (27) | |
EMZL | 265 (50) | 65 (45) | 200 (52) | |
ECOG PS, n (%) | 0.03 | |||
0–1 | 448 (91) | 111 (85) | 337 (93) | |
≥ 2 | 46 (9) | 19 (15) | 27 (7) | |
Stage, n (%) | 0.21 | |||
1–2 | 140 (27) | 31 (22) | 109 (29) | |
3–4 | 376 (73) | 110 (78) | 266 (71) | |
B symptoms, n (%) | 106 (21) | 35 (25) | 71 (19) | 0.12 |
LDH > ULN, n (%) | 135 (27) | 46 (36) | 89 (24) | 0.01 |
Albumin < ULN, n (%) | 80 (16) | 29 (22) | 51 (14) | 0.03 |
B2M > ULN, n (%) | 129 (52) | 35 (53) | 94 (52) | 0.88 |
Monoclonal protein, n (%) | 151 (32) | 62 (47) | 89 (27) | < 0.0001 |
BM involvement, n (%) | 243 (55) | 69 (57) | 174 (55) | 0.59 |
Median WBC, K/uL (range) | 6.2 (0.7–131) | 5.8 (0.7–54.2) | 6.3 (1.6 – 131) | 0.21 |
Median Hgb, g/dL (range) | 12.5 (3.7–18.9) | 12.3 (5.5–15.6) | 12.6 (3.7–18.9) | 0.20 |
First-line treatment, n (%) | 0.02 | |||
Rituximab alone | 296 (56) | 95 (66) | 201 (53) | |
R-chemotherapy | 200 (38) | 42 (29) | 158 (41) | |
Others | 28 (5) | 6 (4) | 22 (6) |